[1] |
孙燕,石远凯.内科肿瘤学[M].5版.北京:人民卫生出版社, 2007:161-162. |
[2] |
李江, 刘鸿生, 刘超英, 等.培美曲赛联合顺铂与多西他赛联合顺铂二线方案治疗晚期肺腺癌的临床对比研究[J].中华肿瘤防治杂志, 2010, 17(14):1127-1128. |
[3] |
张冠中, 焦顺昌.培美曲赛治疗非小细胞肺癌的研究进展[J].山东医药, 2011, 51(15):113-114. |
[4] |
吴尉,朱跃红,袁以军,等.吉西他滨或培美曲赛联合顺铂治疗晚期非小细胞肺癌的临床比较研究[J].临床和实验医学杂志, 2010,9(8):576-577. |
[5] |
Eisenhauer EA, Therasseb P, Bogaertsc J, et al.New respongse evaluation criteria in solid tumours:revised RECIST guideline(version 1.1) [J]. Eur J Cancer, 2009, 45(2):228-247. |
[6] |
Trotti A, Bentzen SM.The need for adverse effects reporting standards in oncology clinical trials[J].J Clin Oncol, 2004, 22(1):19-22. |
[7] |
Rossi A,Maione P,Bareschino MA,et al.The emerging role of hisology in the choice of first-line treatment of advanced nonsmall cell lung cancer:implication in the clinical decision-making[J].Curr Med Chem,2010,17(11):1030-1038. |
[8] |
Scagliotti GV,Parikh P,von Pawel J,et al.Phase Ⅲ study comparing cisplatin plus gemcitatine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced stage non-small cell lung cancer[J].J Clin Oncol,2008,26(21):3543-3551. |
[9] |
胡兴胜, 焦顺昌, 张树才, 等.培美曲赛及吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌安全性和有效性的随机对照研究[J].中国肺癌杂志, 2012, 15(10):569-575. |
[10] |
王丽, 史美祺.培美曲赛联合铂类一线治疗晚期肺腺癌疗效[J].江苏医药, 2012, 38(11):1290-1292. |
[11] |
张玉梅, 李春姗, 陈逸恒.培美曲赛单药维持化疗晚期非小细胞肺癌的疗效观察[J].实用临床医药杂志, 2011, 15(13):48-50. |
[12] |
Adjei AA,Mandrekar SJ,Dy GK,et al.Phase Ⅱ trial of peme-trexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer:NCCTG and SWOG Study N0426[J].J Clin Oncol,2010,28(4):614-619. |
[13] |
狄杰, 周海燕.培美曲赛与多西紫杉醇二线治疗肺非鳞癌的临床比较[J].山东医药, 2011, 51(36):101-102. |
[14] |
韩金娣,方健,聂鋆.培美曲赛治疗晚期肺腺癌的疗效观察[J].中华肿瘤防治杂志, 2011, 18(21):1722-1724. |